Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
simeprevir + rilpivirine
- Development stage
- Unknown
- Lead developer
- Janssen Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Simeprevir (TMC435) is an oral small molecule inhibitor of the hepatitis C virus (HCV) NS3/4A protease, developed for the treatment of chronic HCV genotype 1 infection. It is marketed under the brand name Olysio and was developed by Janssen in collaboration with Medivir[6][8]. Rilpivirine (TMC278) is a diarylpyrimidine nonnucleoside reverse transcriptase inhibitor (NNRTI), used as an antiretroviral agent for HIV-1 infection. It acts by inhibiting HIV-1 reverse transcriptase and has a high genetic barrier to resistance[4][5][7]. Rilpivirine is marketed as Edurant and was also developed by Janssen. The combination of these two drugs represents a multi-antiviral regimen targeting both HCV and HIV infections.
- Brand names
- OlysioEdurant
- Other names
- simeprevirrilpivirine
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseNS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)
Beyond the preview
Go deeper on simeprevir + rilpivirine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on simeprevir + rilpivirine.